The articles selected for CME courses in the June and July issues did not include all of the author’s disclosure statements because of an inadvertent omission during the Journal’s production. The authors had previously disclosed all conflicting interests, as requested. Authors whose disclosure data were not published are presented here.
A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents (Am J Psychiatry 2006; 163:1179–1186): Dr. Wagner has active research support from Eli Lilly, Organon, National Institute of Mental Health, and is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Novartis, Ortho-McNeil, Otsuka, Pfizer, and NIMH Advisory Council. Dr. Kowatch has financial affiliations with Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Astra-Zeneca and Abbott. Dr. Emslie receives grants from Eli Lilly, Organon, Inc., and Forest Laboratories, Inc., and serves as a consultant to Eli Lilly, GlaxoSmithKline, Forest Laboratories, Inc., Pfizer, Inc., and Wyeth-Ayerst, and serves on the Speakers bureau to McNeil. Dr. Findling receives or has received research support, acted as a consultant and/or served on a speaker"s bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Synthelabo, Shire, Solvay, and Wyeth. Dr. Wilens receives grants, serves on the Speakers Bureau or is a consultant to Abbott, Alza / Ortho-McNeil, Cephalon, Glaxo/SKB, Janssen, Lilly, NIDA, NIMH, NICMH, Neurosearch, Novartis, Pfizer, Saegis, Sanofi-Synthelabo, and Shire. Dr. D’Souza and Mr. McCague are employees and stockholders of Novartis Pharmaceuticals Inc. Dr. Wamil discloses past employment at Novartis Pharmaceuticals Corporation and Eisai Medical Research, Inc., and current employment at Sanofi-Aventis. Dr. Berv is a consultant and on the speaker"s bureau for Abbott and on the speaker"s bureaus for Pfizer and Astra Zeneca. Drs. Lehman and Linden report no competing interests.
APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.